文献速递中毒与环境急症消化、代谢与肾脏急症

药物性胃石特征分析:基于VigiBase的描述性研究

Characterizing pharmacobezoar formation: a descriptive analysis from VigiBase.
PubMed 文献 · Clin Toxicol (Phila) · 2025-05-29
一句话结论VigiBase中632例药物性胃石报告以卡比多巴/左旋多巴、喹硫平最常见,68.4%为严重不良反应,急性中毒亚组98.7%为严重报告。

该研究对世界卫生组织VigiBase数据库1968年至2025年3月2日的632份去重个体病例安全报告进行描述性分析,药物性胃石主要涉及男性(318例,50.3%),中位年龄60.0岁(IQR 43.0-71.0岁),432份(68.4%)为严重药物不良反应。最常见药物为卡比多巴/左旋多巴(148例,23.4%)、喹硫平(63例,10.0%)、硫糖铝(46例,7.3%)、硝苯地平(41例,6.5%)和阿司匹林(40例,6.3%)。急性中毒亚组158份报告中女性103例(65.2%),中位年龄43.0岁(IQR 24.0-54.0岁),156份(98.7%)为严重报告,最常见为喹硫平、文拉法辛、布洛芬、阿司匹林、对乙酰氨基酚和劳拉西泮。作者认为药物性胃石虽罕见,但与严重及潜在致命结局相关,需提高临床认识,尤其涉及高危药物时早期识别和适当管理可能尤为重要。

要点

  • VigiBase共632份药物性胃石报告,432份(68.4%)为严重药物不良反应,中位年龄60.0岁(IQR 43.0-71.0岁),男性318例(50.3%)。
  • 最常见药物为卡比多巴/左旋多巴148例(23.4%)、喹硫平63例(10.0%)、硫糖铝46例(7.3%)、硝苯地平41例(6.5%)、阿司匹林40例(6.3%)。
  • 急性中毒亚组158份报告中156份(98.7%)为严重报告,女性103例(65.2%),中位年龄43.0岁(IQR 24.0-54.0岁)。
  • 急性中毒亚组最常见药物为喹硫平、文拉法辛、布洛芬、阿司匹林、对乙酰氨基酚和劳拉西泮。
  • 作者认为药物性胃石虽罕见,但与严重及潜在致命结局相关,涉及高危药物时早期识别和适当管理可能尤为重要。

适用人群与场景

  • VigiBase中1968年至2025年3月2日记录的所有去重个体病例安全报告中与药物性胃石相关的报告。
  • 急性中毒亚组为报告中包含至少一个与药物过量、误用或自杀行为相关首选术语的病例。

研究设计与关键结果

  • 研究类型为基于VigiBase的描述性分析,共分析632份去重个体病例安全报告。
  • 总体中男性318例(50.3%),中位年龄60.0岁(IQR 43.0-71.0岁),严重药物不良反应432份(68.4%)。
  • 最常见药物为卡比多巴/左旋多巴148例(23.4%)、喹硫平63例(10.0%)、硫糖铝46例(7.3%)、硝苯地平41例(6.5%)、阿司匹林40例(6.3%)。
  • 急性中毒亚组158份报告中女性103例(65.2%),中位年龄43.0岁(IQR 24.0-54.0岁),严重报告156份(98.7%)。
  • 急性中毒亚组最常见药物为喹硫平、文拉法辛、布洛芬、阿司匹林、对乙酰氨基酚和劳拉西泮。

证据类型、等级与局限

  • 证据类型为基于自发报告数据库的描述性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为药物性胃石虽罕见,但与严重及潜在致命结局相关,需提高临床认识。
  • 作者认为涉及高危药物时早期识别和适当管理可能尤为重要。
  • 作者指出精神药物高发提示需在高危人群(尤其合并精神疾病者)中开展针对性预防。
  • 作者指出卡比多巴/左旋多巴频繁报告可能反映帕金森病等伴胃动力延迟的 underlying 情况。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Pharmacobezoars are concretions of drugs that can persist within the gastrointestinal tract and can lead to mechanical obstruction and pharmacological toxicity. We aimed to provide a descriptive analysis of reported cases of pharmacobezoar in VigiBase, the World Health Organization global database of adverse event reports for medicines and vaccines.

METHODS: We conducted a descriptive analysis of all de-duplicated individual case safety reports related to pharmacobezoars recorded in VigiBase, from its inception in 1968 to March 2, 2025. In a subgroup analysis, we selected reports containing at least one Preferred Term related to drug overdose, misuse, or suicidal behavior to identify potential cases of acute intoxication.

RESULTS: A total of 632 individual case safety reports related to pharmacobezoars were analyzed. These primarily involved male patients (n = 318; 50.3%), with a median age of 60.0 years (IQR 43.0-71.0 years). Overall, 432 reports (68.4%) described serious adverse drug reactions. The most frequently involved drugs were carbidopa/levodopa (n = 148; 23.4%), quetiapine (n = 63; 10.0%), sucralfate (n = 46; 7.3%), nifedipine (n = 41; 6.5%), and acetylsalicylic acid (n = 40; 6.3%). The subgroup analysis included 158 reports related to acute intoxications, mostly involving female patients (n = 103; 65.2%), with a median age of 43.0 years (IQR 24.0-54.0 years). Almost all were serious (n = 156; 98.7%), with quetiapine, venlafaxine, ibuprofen, acetylsalicylic acid, paracetamol, and lorazepam most frequently reported.

DISCUSSION: The findings highlight the clinical severity and heterogeneous presentation of pharmacobezoars. Carbidopa/levodopa was frequently reported, possibly reflecting underlying conditions such as Parkinson disease with delayed gastric motility. The high prevalence of psychotropics underscores the need for targeted prevention in at-risk populations, particularly those with psychiatric comorbidities.

CONCLUSIONS: While pharmacobezoars are rare, their association with serious and potentially fatal outcomes warrants increased clinical awareness. Early recognition and appropriate management may be particularly important in cases involving high-risk drugs.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Carollo M, Luxi N, Crisafulli S, et al. Characterizing pharmacobezoar formation: a descriptive analysis from VigiBase. Clin Toxicol (Phila). 2025. PMID: 40438945. doi:10.1080/15563650.2025.2508428

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。